Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy [Yahoo! Fin...
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
Capricor Therapeutics Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022) Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017) Global Statistical Test (GST) composite endpoint showed significant overall treatment benefit Duchenne Video Assessment (DVA) showed approximately 83% slowing of disease progression (p=0.018), consistent with mid-level (elbow) PUL v2.0 results Deramiocel BLA currently under FDA review with a PDUFA target action date of August 22, 2026 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced additional analyses and new functional outcomes data from the Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy (DMD), which were presented yesterday at the 2026 Muscular Dystrophy Association (MDA) Cl
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? [Yahoo! Finance]Yahoo! Finance
- Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics (CAPR) had its price target raised by B. Riley Financial, Inc. from $50.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Capricor Therapeutics (CAPR) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $58.00 price target on the stock, up from $45.00.MarketBeat
- Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035 [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 3/12/26 - Miss
CAPR
Sec Filings
- 3/17/26 - Form 10-K
- 3/12/26 - Form 8-K
- 3/10/26 - Form 8-K
- CAPR's page on the SEC website